Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 645Pancreatic Neoplasms 392Carcinoma, Hepatocellular 308Stomach Neoplasms 252Rectal Neoplasms 182Colonic Neoplasms 182Esophageal Neoplasms 171Carcinoma, Non-Small-Cell Lung 169Breast Neoplasms 150Neoplasms 135Neoplasm Metastasis 131Ovarian Neoplasms 123Cholangiocarcinoma 112Lung Neoplasms 108Liver Neoplasms 107Gastrointestinal Neoplasms 98Melanoma 87Biliary Tract Neoplasms 77Prostatic Neoplasms 75Endometrial Neoplasms 74Esophageal Squamous Cell Carcinoma 67Carcinoma, Renal Cell 57Squamous Cell Carcinoma of Head and Neck 54Sarcoma 54Uterine Cervical Neoplasms 51Adenocarcinoma Of Esophagus 47Head and Neck Neoplasms 46Urinary Bladder Neoplasms 42Triple Negative Breast Neoplasms 39Anus Neoplasms 36

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Gastric Adenocarcinoma × Gastrointestinal × 90 days × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡